Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers

Chen, Mengzhu; Liu, Xiu Ying; Du, Jie; Wang, Xiu‐Jie; Lei, Xia

doi:10.18632/oncotarget.13346

Cited by 58 publications

(62 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LUSC, accounting for 30% of all lung cancer types, is a horrible threat to individual life. 27,28 Modern advanced methods like surgery, chemotherapy and radiotherapy have been applied to treat LUSC. 28,29 Nevertheless, LUSC patients still present a dismal prognosis with a low overall 5-year survival rate due to tumor metastasis and recurrence.…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis

He¹,

Zhou²,

Li³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Lung squamous cell carcinoma (LUSC) accounts for approximately 30% of all lung cancers that possesses the highest occurrence and mortality in all cancer types. Long noncoding RNAs have been reported to modulate tumor development for several decades. Aim of the Study: This research aims to investigate the role of MAGI2-AS3 in LUSC. Methods: RT-qPCR tested genes (including MAGI2-AS3, miR-374a/b-5p and CADM2) expression. Cell proliferation was detected by colony formation and EdU assays. Cell migration and invasion were evaluated by transwell assay. Flow cytometry analysis of apoptotic cells and Western blot analysis on apoptosis-related genes were applied to measure cell apoptosis. Nuclear-cytoplasmic fractionation and FISH assay positioned MAGI2-AS3. The combination between miR-374a/b-5p and MAGI2-AS3 (or CADM2) was determined by luciferase reporter assay and RIP assay. Results: MAGI2-AS3 inhibited the proliferative, migratory and invasive capability of LUSC cells with upregulated expression. Additionally, MAGI2-AS3 overexpression promoted cell apoptosis. We discovered that MAGI2-AS3 was located in the cytoplasm. Hereafter, we found out that MAGI2-AS3 targeted miR-374a/b-5p. CADM2 was targeted by miR-374a/ b-5p. Finally, rescue assays indicated that the promoting effects of miR-374a/b-5p amplification on biological activities were restored by CADM2 addition. Conclusion: In conclusion, lncRNA MAGI2-AS3 suppressed LUSC by regulating miR-374a/b-5p/CADM2 axis, which might potentially serve as a therapeutic marker for LUSC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis

He¹,

Zhou²,

Li³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Moreover, it has been found that mutations in cell cycle genes can affect the differentiation of squamous cells in the course of modern anticancer treatment research . Pathways in cancer, which describes important signaling pathways such as Wnt signaling and T‐cell receptor signaling, is also an important factor in the progression of NSCLC and development of squamous cell carcinoma of the lung …”

Section: Discussionmentioning

confidence: 99%

“…53,54 Pathways in cancer, which describes important signaling pathways such as Wnt signaling and T-cell receptor signaling, is also an important factor in the progression of NSCLC and development of squamous cell carcinoma of the lung. 55,56 To further validate and screen the target genes, we performed a topological analysis in the PPI network. The six F I G U R E 4 PPI network of lung squamous cell carcinoma related target genes and related genes.…”

mentioning

confidence: 99%

MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets

Gao

Feng

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background With the development in research, the importance of microRNAs (miRNAs) in the occurrence and metastasis, and prognosis of lung squamous cell carcinoma (LUSC) have received extensive attention. This study aims to identify new biomarkers and pivotal genes associated with LUSC prognosis through bioinformatics. Materials and methods We downloaded miRNA and messenger RNA samples related to LUSC from The Cancer Genome Atlas (TCGA) database. Following initial data screening and preprocessing, we utilized the R platform and a range of analysis tools (miRDB, TargetScanHuman7.2, DAVID, and Cytoscape_v3.5.1) to analyze the TCGA data and identify highly specific and sensitive biomarkers. Results We finally identified 12 miRNAs and six central genes closely related to the overall survival of patients with LUSC. We found that high expression of 7 miRNAs (miR‐301b, miR‐383, miR‐512, miR‐515, miR‐525, miR‐577, and miR‐5682) and low expression of five miRNAs (miR‐448, miR‐486, miR‐4732,miR‐4732, miR‐516, and miR‐1911) can significantly improve the overall survival rate of patients with LUSC. The six central genes DLGAP5, CENPA, CHEK1, LRRK2, CALB1, and TOP2A are directly or indirectly involved in the formation and metastasis of LUSC and could, therefore, be considered as target genes for drug therapy. Conclusion With the development in research, the importance of miRNAs in the occurrence and metastasis and prognosis of LUSC have received extensive attention. This study aims to identify new biomarkers and pivotal genes associated with LUSC prognosis through bioinformatics.

show abstract

“…1 Despite advances in the diagnosis and treatment of LUAD, its prognosis remains poor. 2 Therapies targeted at suppressing driver genes, including epidermal growth factor receptor (EGFR, HGNC ID: 8236) and anaplastic lymphoma kinase (ALK, HGNC ID: 427), have been shown to extend the survival time and improve the quality of life of LUAD patients. However, the emergence of resistance limits the clinical utility of such drugs.…”

Section: Introductionmentioning

confidence: 99%

FANCI Cooperates with IMPDH2 to Promote Lung Adenocarcinoma Tumor Growth via a MEK/ERK/MMPs Pathway

Zheng¹,

Li²

2020

OTT

View full text Add to dashboard Cite

Purpose: Fanconi anemia complementation group I (FANCI) is a key protein in ribosome biogenesis and DNA repair. Here, we aimed to determine the clinical significance, prognostic value and biology functions of FANCI in lung adenocarcinoma (LUAD). Methods: The expression of FANCI in LUAD tissue and its relationship with patient outcomes were assessed using bioinformatics analysis, as well as quantitative reverse-transcription PCR (qRT-PCR) and Western blot analysis of LUAD tissue and adjacent normal lung tissue. The chisquared test and Cox regression analysis were used to analyze the clinical significance of FANCI expression. The biological effects of FANCI knockdown in human LUAD cell lines were investigated by analysis of proliferation, colony formation, cell cycle distribution, migration, and invasion in vitro, and monitoring of tumor xenograft growth in vivo. FANCI interactions with IMPDH2 and involvement in MEK/ERK/MMPs signaling were analyzed using coimmunoprecipitation assays, immunofluorescence microscopy, and Western blotting. Results: FANCI was identified as a hub gene for LUAD. FANCI expression was upregulated in LUAD tissues compared with normal lung tissues and was positively associated with lymphatic metastasis, distant metastasis, and poor outcome. FANCI was also an independent prognostic factor in LUAD patients. Knockdown of FANCI in LUAD cell lines decreased their proliferation, migration, invasion, and cell cycle progression in vitro, and decreased the growth of xenografts in mice. Direct binding of FANCI to IMPDH2 decreased IMPDH2 degradation, regulated activation of MEK/ERK/MMPs signaling. Overexpression of IMPDH2 reversed the inhibitory effects of FANCI knockdown. Conclusion: FANCI may act as an oncogene in LUAD by cooperating with IMPDH2 to promote cell proliferation via the MEK/ERK/MMPs pathway. These results identify FANCI as a potential prognostic biomarker and therapeutic target for LUAD.

show abstract

Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers

Cited by 58 publications

References 61 publications

<p>Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis</p>

<p>Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis</p>

MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets

<p>FANCI Cooperates with IMPDH2 to Promote Lung Adenocarcinoma Tumor Growth via a MEK/ERK/MMPs Pathway</p>

Contact Info

Product

Resources

About